Influenza Antigen Articles & Analysis
4 articles found
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development. ...
Longlong Si's research group from the Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, published a research titled "Generation of a live attenuated influenza A vaccine by proteolysis targeting" in Nature Biotechnology. Using influenza virus as a model virus, the team established the technology of protein degradation targeting virus as an ...
MADISON, Wis.–(BUSINESS WIRE)–An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu. UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccineTweet this CoroFlu will build on the ...
Abstract Both influenza A and B viruses cause outbreaks of seasonal influenza resulting in significant morbidity and mortality. There are two antigenically distinct lineages of influenza B virus, Yamagata lineage (YL) and Victoria lineage (VL). Since both B lineages have been co-circulating for years, more than 70% of influenza vaccines currently manufactured are quadrivalent consisting of ...